HC Wainwright Issues Pessimistic Forecast for CRBP Earnings

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) – Stock analysts at HC Wainwright decreased their FY2025 earnings estimates for shares of Corbus Pharmaceuticals in a research report issued to clients and investors on Thursday, November 13th. HC Wainwright analyst A. Maldonado now forecasts that the biopharmaceutical company will post earnings of ($6.03) per share for the year, down from their prior estimate of ($5.82). HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Corbus Pharmaceuticals’ Q4 2025 earnings at ($1.36) EPS, FY2026 earnings at ($5.34) EPS, FY2027 earnings at ($6.49) EPS, FY2028 earnings at ($4.92) EPS and FY2029 earnings at ($2.76) EPS.

Other equities research analysts have also issued research reports about the stock. Oppenheimer reduced their price target on shares of Corbus Pharmaceuticals from $56.00 to $53.00 and set an “outperform” rating for the company in a research report on Wednesday, August 6th. Royal Bank Of Canada reduced their target price on shares of Corbus Pharmaceuticals from $55.00 to $53.00 and set an “outperform” rating for the company in a report on Thursday, November 13th. Wedbush increased their price target on shares of Corbus Pharmaceuticals from $31.00 to $38.00 and gave the stock an “outperform” rating in a research report on Monday, October 20th. B. Riley raised shares of Corbus Pharmaceuticals to a “strong-buy” rating and set a $28.00 price objective for the company in a research report on Wednesday, July 30th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, Corbus Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $44.38.

Corbus Pharmaceuticals Stock Performance

CRBP stock opened at $12.01 on Monday. The company has a market cap of $147.18 million, a price-to-earnings ratio of -2.52 and a beta of 2.69. The business’s 50-day moving average is $13.44 and its two-hundred day moving average is $10.22. Corbus Pharmaceuticals has a fifty-two week low of $4.64 and a fifty-two week high of $20.56.

Corbus Pharmaceuticals (NASDAQ:CRBP) last released its quarterly earnings results on Wednesday, November 12th. The biopharmaceutical company reported ($1.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.80) by ($0.10).

Insiders Place Their Bets

In other news, CFO Sean F. Moran sold 12,981 shares of the stock in a transaction on Friday, October 24th. The shares were sold at an average price of $17.02, for a total value of $220,936.62. Following the completion of the sale, the chief financial officer directly owned 73,313 shares of the company’s stock, valued at $1,247,787.26. This represents a 15.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Yuval Cohen sold 8,973 shares of Corbus Pharmaceuticals stock in a transaction on Monday, October 27th. The shares were sold at an average price of $17.14, for a total transaction of $153,797.22. Following the transaction, the chief executive officer owned 138,187 shares in the company, valued at approximately $2,368,525.18. This trade represents a 6.10% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 41,674 shares of company stock valued at $713,870. Corporate insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Corbus Pharmaceuticals

A number of hedge funds have recently made changes to their positions in CRBP. Velan Capital Investment Management LP raised its stake in Corbus Pharmaceuticals by 3.4% during the 3rd quarter. Velan Capital Investment Management LP now owns 61,000 shares of the biopharmaceutical company’s stock valued at $772,000 after purchasing an additional 2,000 shares during the period. Mariner LLC grew its holdings in Corbus Pharmaceuticals by 34.0% during the 3rd quarter. Mariner LLC now owns 20,840 shares of the biopharmaceutical company’s stock valued at $264,000 after buying an additional 5,289 shares in the last quarter. ADAR1 Capital Management LLC purchased a new stake in Corbus Pharmaceuticals during the 3rd quarter valued at approximately $129,000. Corton Capital Inc. bought a new stake in shares of Corbus Pharmaceuticals during the second quarter valued at approximately $86,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Corbus Pharmaceuticals by 2.1% in the third quarter. Vanguard Group Inc. now owns 612,030 shares of the biopharmaceutical company’s stock worth $7,742,000 after buying an additional 12,535 shares in the last quarter. Institutional investors own 64.64% of the company’s stock.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.